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Recent Advances in the Treatment of Malignant Pleural
Mesothelioma
Suresh S. Ramalingam, MD,* and Chandra P. Belani, MD†
Malignant pleural mesothelioma clinically manifests after decades
of initial exposure to etiologic agents, such as asbestos, and presents
with nonspecific symptoms such as dyspnea, pain, or weight loss. In
patients with limited, resectable disease, surgical therapy with ex-
trapleural pneumonectomy or pleurectomy is recommended, al-
though, it is unclear which approach is superior. Radiation has a
limited role and is used primarily for palliation. The palliative
efficacy of traditional chemotherapeutic agents and combination
regimens is modest at best. The combination of cisplatin and
pemetrexed, a novel multitargeted antifolate agent, is the approved
“standard of care” for patients with unresectable malignant pleural
mesothelioma. A number of molecularly targeted agents are cur-
rently under evaluation for mesothelioma such as the Histone
deacetylase (HDAC) inhibitors that have demonstrated promising
anticancer activity. Vorinostat, a small molecule inhibitor of HDAC,
which targets select members of class I and II HDACs, has shown
early evidence of activity and is currently being evaluated in a
randomized study for patients who progress with standard therapy
for advanced mesothelioma. It is hoped that the HDAC inhibitors
and other novel targeted agents will pave the way for improved
outcomes for patients with this disease.
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Malignant pleural mesothelioma (MPM) is a rare malig-nancy, which has been the subject of much attention
because of its long recognized link to asbestos and poor
outcome.1 Because of the 30- to 40-year lag time between
exposure to asbestos and the development of MPM, the
incidence of the disease is expected to continue to increase
over the next decade.2,3 Most patients with MPM are diag-
nosed in the sixth or seventh decade of life. Although there is
no evidence that tobacco causes MPM, it does, in combina-
tion with asbestos, seem to synergistically increase the risk of
MPM. Other etiologies have also been proposed including
radiation and Simian Virus (SV40).4
There are three primary histologic subtypes: epithelial,
sarcomatous or fibrosaracomatous, and mixed.5 The first is
generally considered to have the best prognosis, whereas the
sarcomatous type portends a poor prognosis. Death from
MPM typically results from local invasion, rather than distant
metastases. Indeed, few patients have distant metastases at
the time of diagnosis. Nevertheless, autopsy studies have
reported that as many as 80% of patients have widespread
disease on examination.6
Computed tomography (CT) and magnetic resonance
imaging (MRI) scans are considered the most accurate radio-
graphic studies in the evaluation of MPM at this time.7,8 In
both, the most characteristics findings are pleural thickening,
often focal, and pleural effusion. However, it is unclear if one
or the other is the superior imaging method. Two separate
reports comparing the accuracies of CT and MRI have been
published by Heelan et al.9 and Patz et al.,10respectively, and
the authors concurred that they are equivalent. Although MRI
may be slightly superior in evaluating chest wall invasion, CT
is favored for assessment of mediastinal involvement.
The clinico-pathologic factors most commonly linked
with a better outcome are histology (epithelial), performance
status (Eastern Cooperative Oncology Group 0 or 1), and
stage.11,12 Other variables that have been reported, but not
confirmed, to influence survival or response are duration of
symptoms, gender, leukocyte and platelet count, and age.
THERAPEUTIC OPTIONS
Surgery
Complete surgical resection has a curative potential in
selected patients with MPM. However, not all patients with
MPM present with early stage disease that is amenable to
surgical resection. The two surgical procedures that are gen-
erally considered are extrapleural pneumonectomy (EPP) and
pleurectomy with dectorication. EPP entails the en bloc
resection of the lung, as well as relevant lymph nodes,
adherent pericardium, and involved diaphragm. Though ini-
tial reports noted promising survival with surgical interven-
tion in patients with stage I disease, particularly with epithe-
lial histology, the operative mortality and morbidity was high
at 10 to 20%.13 Combined with improvements in postopera-
tive care, data from experienced centers, have noted the
mortality rate in recent times to be approximately 5 to
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10%.14,15 Schipper et al.16 reported a large series of patients
treated with MPM treated at their institution (N  285
patients). Seventy-three patients underwent EPP of whom
approximately 50% had major complications. The median
survival for patients who underwent EPP was 16 months and
the 3-year survival rate was only 14%. Pleurectomy and
decortication is associated with a lower postoperative com-
plications rate but has a higher rate of local recurrence.
It is unclear whether EPP or pleurectomy with decor-
tication is clearly superior, as no prospective randomized
comparisons have been performed.17 A report from the Lung
Cancer Study Group demonstrated in a nonrandomized study
that patients who were treated with EPP had similar survival
to those treated with nonradical surgery.18 Similarly, Allen et
al.,19 reported comparable outcomes for patients treated with
EPP and pleurectomy. Although these reports suggest that
there is no benefit to EPP, they also note that local recurrence
was substantially lower with EPP. Recently, Flores et al.20
studied data from 663 consecutive patients who underwent
either EPP or pleurectomy with decortication across three
institutions. The postoperative mortality rate was higher for
EPP (7%) compared with pleurectomy (4%). The hazard ratio
for survival favored the use of pleurectomy over EPP. The
overall survival with EPP was inferior based on an univariate
analysis, when compared with pleurectomy with decortica-
tion. Female gender and the use of multimodality therapy
were associated with a better outcome. EPP was associated
with a lower rate of local recurrence. Interpretation of these
results is limited by potential variations in eligibility criteria
for the two procedures at the three participating institutions.
Thus several questions remain unanswered regarding the
role of surgery in the treatment of MPM. Appropriate patient
selection criteria, the type of surgery, and the timing of surgery
are often chosen based on individual institutional protocols.
MULTIMODALITY THERAPY
An active avenue of exploration in MPM is the role of
multimodality therapy in an attempt to minimize the occur-
rence of local, and distant metastasis after, if possible, resec-
tion, or at least maximal reduction of the tumor. The largest
experience reported to date is that of Sugarbaker and Norb-
erto,21 who treated 183 patients over nearly 2 decades. Pa-
tients who underwent EPP were subsequently treated with
combination chemotherapy regimen of cyclophosphamide,
doxorubicin, and cisplatin, and later paclitaxel and carbopla-
tin followed by 3000 cGy of radiation. In their experience,
operative mortality was less than 4%, and major morbidity,
primarily cardiac arrhythmia, respiratory failure, aspiration,
pulmonary embolism, and infection was noted in approxi-
mately 30% of patients. The median survival was 19 months,
and 2-year survival rate was 38%. Fifteen percent of patients
survived 5 years. The use of tri-modality therapy has also
been studied by other groups. Batirel et al.22 studied the
strategy of EPP followed by hemithoracic radiation (54 Gy).
Subsequently, all patients were treated with platinum-based
chemotherapy. Though this was a small study with only 20
patients, the approach was safe and was associated with a
median survival of 20 months.
The use of intracavitary chemotherapy after pleurectomy
was studied by Richards et al.23 in a phase I/II study. Forty-four
patients with MPM underwent pleurectomy and were given
intrapleural hyperthermic cisplatin with an exposure time of 1
hour. The dose of cisplatin was escalated in sequential cohorts of
patients. The procedure was tolerated well and was associated
with a median survival of 13 months. The major adverse events
reported included atrial fibrillation and venous thrombosis. The
postoperative mortality rate was 11%. The study had a higher
proportion of patients with sarcomatoid histology, which is
generally resistant to chemotherapy. These results are promising,
but can only be recommended in the presence of an experienced
team of surgeons and oncologists.
The availability of an efficacious combination chemother-
apy regimen (cisplatin-pemetrexed) provides the opportunity for
improved multidisciplinary care. In a phase II study, Krug et
al.24 treated 77 MPM patients with four cycles of cisplatin-
pemetrexed. EPP followed by hemithoracic radiation was ad-
ministered to patients with objective response or stable disease
with chemotherapy. Overall, 83% of the patients received all
four cycles of chemotherapy. Out of 54 patients who underwent
surgery, 87% were able to undergo EPP. The median survival
was promising at 17 months, based on a preliminary report. This
study demonstrates the feasibility of neoadjuvant chemotherapy
in patients with resectable MPM, and further studies are essen-
tial to define patient subpopulations that derive benefit from
combined-modality therapy.
RADIATION
Radiotherapy has been evaluated for palliation, primary
therapy or after surgical intervention in patients with MPM.
Because MPM is a diffuse disease with frequent involvement of
neighboring organs such as the lung, esophagus, heart, and liver,
the use of radiation as primary therapy is not feasible in a
majority of the patients. In a small study of 12 patients who
underwent primary radiation therapy, two fatal complications of
hepatitis and myelopathy were noted.25 In another study by
Linden et al.,26 radiation was used alone or in combination with
chemotherapy for the treatment of MPM. Thirty-one patients
received radiation therapy alone to a dose of 40 Gy. There was
one partial response and the median survival was 6 months.
Nearly, all patients developed radiation induced pulmonary
fibrosis. For these reasons, radiation is not recommended as
primary therapy for mesothelioma. Nevertheless, radiation can
be used for palliation of chest pain or painful chest wall recur-
rences after surgical therapy. In a prospective study by Bissett et
al.,27 22 MPM patients with chest pain were treated with 30 Gy
of external beam radiation to the involved hemithorax. Though
improvement in pain was noted in 13 out of 19 evaluable
patients at 1 month after therapy, the benefit was short lived.
Majority of the patients had worsening pain by 3 months. The
use of a slightly higher dose of radiation was reported to be
associated with a greater degree of benefit in another study.28
Out of 19 patients who received palliative radiation, the use of
40 Gy over 4 weeks appeared to be associated with the best
results.
Radiotherapy has also been evaluated as part of multimo-
dality therapy for patients with MPM. Patients who underwent
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surgical resection for MPMwere treated with 54 Gy of hemitho-
racic external beam radiation in a phase II study.29 Out of the 57
patients who received postoperative radiotherapy, the median
survival was 34 and 10 months, respectively, for patients with
early stage (I and II) and advanced stage (III and IV) disease,
respectively. The treatment was tolerated well overall with one
case of tracheo-esophageal fistula being the most severe toxicity
reported. There was excellent local control with postoperative
radiotherapy, and majority of the recurrences occurred at sys-
temic sites. High-dose intraoperative radiotherapy has also been
evaluated in patients in an effort to improve the local control rate
for patients with surgically resectable MPM. However, this
approach was associated with a high degree of toxicity and has
not been evaluated further.30
More recently, intensity-modulated radiotherapy (IMRT)
has been studied for therapy for MPM. This technique allows for
improved dose distribution to areas at risk for recurrence and a
lower exposure of adjacent organs to the radiation. In a cohort of
100 patients who underwent EPP, IMRT with a median dose of
45 Gy was administered to 63 patients.31 The median overall
survival was higher (14.4 months) for patients who received
IMRT, whereas patients without IMRT had a median survival of
10 months. Only three patients had in-field recurrences with
IMRT. Although these results are encouraging, the results from
another small study of 13 patients urge caution with this ap-
proach.32 There was one case of fatal pulmonary toxicity in a
patient who received IMRT after EPP. This study also docu-
mented a low rate of local recurrence, though the follow-up
duration was short. Allen et al.33 documented, noted fatal pul-
monary toxicity in 6 out of 13 patients treated with IMRT after
chemotherapy and EPP for MPM. Therefore, it is important that
IMRT be used as part of clinical trials for the treatment of MPM.
CHEMOTHERAPY
A wide array of chemotherapeutic agents has been eval-
uated for the treatment of MPM.34 Initial studies noted antican-
cer activity with older agents such as methotrexate, doxorubicin,
and platinum compounds.35–38 More recently, newer agents such
as taxanes, gemcitabine, pemetrexed, and raltitrexed have been
noted to have promising anticancer activity with a favorable
tolerability profile (Table 1 and 2 ).39–44 Until recently, studies
that evaluated combination of these agents had failed to dem-
onstrate a substantial increase in survival, although response
rates were often improved. In a recent trial, pemetrexed, a
multitargeted antifolate, in combination with cisplatin resulted in
improved survival for patients with mesothelioma.45 The results
of this large clinical trial, have established a “new standard” for
the treatment of patients with advanced MPM.
ANTIFOLATE AGENTS
High-dose methotrexate has demonstrated anticancer ac-
tivity in MPM. Administered at 3 g/m2 every 10 to 21 days, with
leucovorin rescue, methotrexate demonstrated responses in 37%
of 60 patients including one complete response, with a median
survival of 11 months.35 Other antifolates such as edatrexate and
trimetrexate are less active in MPM in trials conducted by the
Cancer and Leukemia Group B (CALGB). Kindler et al.46
reported 2 series of patients with trimetrexate for unresectable
MPM. Patients received 5 days of trimetrexate at doses of 6 or
10 mg/m2 IV. Responses were noted in 12% of patients at both
administered doses, though the higher dose level resulted in a
greater proportion of patients with stable disease, and longer
time to treatment failure, and duration of median survival. The
main side effects were hematologic in nature, with dose depen-
dent nausea, vomiting, and stomatitis. Subsequently, edatrexate
with or without leucovorin was evaluated by the CALGB.
Administered at 80 mg/m2 iv on a weekly schedule, edatrexate
generated responses in 25% of 20 treated patients. Meanwhile,
the same dose and schedule of edatrexate in combination with
leucovorin rescue caused tumor regression in 6 of 38 (16%) of
patients. The median survival was 9.6 and 6.6 months, respec-
tively, on these two schedules. The toxicity, however, was
substantially greater in the regimen without leucovorin, primar-
ily mucositis, nausea and vomiting, and a macular rash. Ralti-
trexed, another novel antifolate compound has also demon-
strated anticancer activity in the treatment of mesothelioma. In a
phase II study conducted by Baas et al.,44 a promising response
rate of 20% was noted. This led to further evaluation of this
agent, in combination with cisplatin in a phase III trial sponsored
by the European Organisation for Research and Treatment of
Cancer Lung Cancer Group and the National Cancer Institute
(NCI) of Canada.47
ANTHRACYCLINES
Doxorubicin has been evaluated in multiple trials for
the treatment of MPM.37,43 When administered at 60 mg/m2
iv every 3 weeks, responses have been demonstrated in 10 to
15% of patients, with a median survival of 8 to 10 months.
Other anthracyclines, such as epirubicin and mitoxantrone
have also yielded similar results.48,49 Another anthracycline,
detorubicin, had promising results in a phase II study, includ-
TABLE 1. Gemcitabine for Mesothelioma
Author Treatment N
RR
(%)
Median
Survival
Van Meerbeeck et al.76 Gem 27 7 8 mo
Kindler et al.77 Gem 17 0 4.7 mo
Nowak and Byrne78 Gem  Cis 53 33 11.2 mo
Byrne et al.52 Gem  Cis 21 48 41 wk
Van Haarst et al.79 Gem  Cis 29 16 9.6 mo
Favaretto et al.53 Gem  Carbo 50 26 66 wk
RR, Response rate.
TABLE 2. Taxanes in Mesothelioma
Author Regimen N RR
Median
Survival
Van Meerbeeck et al.40 Paclitaxel 25 0 39 wk
Vogelzang et al.41 Paclitaxel
(high dose)
39 95 5 mo
Vorobiof et al.80 Docetaxel 30 10% 12 mo
Belani et al.81 Docetaxel 20 5% 4 mo
RR, Response rate.
Ramalingam and Belani Journal of Thoracic Oncology • Volume 3, Number 9, September 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer1058
ing a 43% response rate in 21 patients, and a median survival
of 17 months, with a 60% 1-year-survival.50 Unfortunately,
serious cardiac toxicity was common, and no further research
with this agent has been conducted.
PLATINUM COMPOUNDS AND OTHER
NOVEL AGENTS
Cisplatin and carboplatin have been evaluated in a
number of trials and have demonstrated response rates of 10
to 20%. Both cisplatin and carboplatin seem to have compa-
rable efficacy. The taxanes have yielded modest efficacy,
with disease stabilization being the best response in most
studies.40,41 Multiple phase II studies have demonstrated
anticancer activity for gemcitabine in the treatment of
MPM.39 Response rates of approximately 0 to 31% have been
reported in the setting of advanced stage disease. This has
prompted the evaluation of gemcitabine in combination of a
platinum compound for front-line therapy for MPM.
COMBINATION CHEMOTHERAPY
Combination chemotherapy is now the standard treatment
approach for advanced MPM. A number of combination regi-
mens have been evaluated in phase II studies.37,51,52 Both the
platinols and doxorubicin exhibit preclinical synergy with mul-
tiple chemotherapeutic agents for the treatment of MPM. Hence,
combination regimens that include a platinum compound and an
anthracycline have been extensively evaluated in several phase
II studies.37 The combination of doxorubicin and cisplatin with
or without cyclophosphamide administered every 3 weeks re-
sulted in response rate of less than 25%. The median survival
was approximately 8 to 10 months. The Gemcitabine when
combined with cisplatin or carboplatin has also been reported to
be effective, with responses in 47% and 20% of patients,
respectively.52,53 In the former study, median survival was 41
weeks, and 40% of patients were alive 1 year after therapy. In
addition, the regimen was well tolerated in this group of patients
who often are older, and with comorbidities.
PEMETREXED
Pemetrexed is an antifolate that exerts anticancer effect
by inhibiting three different enzymes that are necessary for
folate metabolism, purine, and pyrimidine synthesis.54 These
enzymes are dihydrofolate reductase, thymidine synthase
(TS), and glycinamide ribonucleotide formyl transferase. A
unique folate transport mechanism with a high affinity for
pemetrexed has been identified in mesothelioma cell lines.
This could, at least in part, explain the higher degree of
antitumor activity noted with pemetrexed in MPM. Polyglu-
tamated pemetrexed is a potent inhibitor of TS and glyci-
namide ribonucleotide formyl transferase. Preliminary evi-
dence of anticancer activity against mesothelioma with
pemetrexed was observed in phase I trials.55 In a phase I
study of the combination of cisplatin and pemetrexed, partial
responses were observed in 5 out of 11 patients with MPM.56
This was further substantiated in a study by Calvert and
colleagues who reported 8 responses in 25 patients with
MPM treated with the combination of carboplatin and pem-
etrexed as part of a phase I trial. This formed the rationale for
evaluation of this combination for patients with MPM.
A phase II study evaluated the antitumor activity of
pemetrexed in patients with previously untreated mesothelio-
ma.57 Sixty-four patients were treated with pemetrexed at a dose
of 500 mg/m2 IV administered every 3 weeks. Nine patients
(14%) experienced partial response. The median survival was
10.7 months. Forty-three patients in the study received supple-
mentation with vitamin B12 and folic acid to reduce the toxicity
associated with the use of pemetrexed. Patients treated with
vitamin supplementation had a better overall survival than those
who did not receive vitamin supplementation (13 versus 8
months). The incidence of both hematological and nonhemato-
logical toxicities was lower in patients who received vitamin
supplements. Vitamin supplementation was instituted based on a
study that evaluated the predictive factors for severe toxicity in
patients treated with pemetrexed. This multivariate analysis of
data from 246 patients treated with pemetrexed demonstrated a
higher incidence of diarrhea, mucositis, neutropenia, and throm-
bocytopenia in patients with higher pretreatment plasma levels
of total homocysteine and methylmalonic acid.58 Supplementa-
tion of vitamin B12 and folic acid was done to decrease the
levels of H and methylmalonic acid in an effort to decrease
toxicity.
Vogelzang et al.45 conducted a randomized phase III trial
to evaluate the efficacy of the combination of cisplatin and
pemetrexed. Patients with previously untreated MPM were ran-
domized to either treatment with cisplatin and pemetrexed or
therapy with pemetrexed alone. A total of 456 patients partici-
pated in the study, which was conducted at multiple institutions
from several countries the world over. The primary end point of
the study was overall survival and secondary endpoints included
response rate, time to progression, and duration of response. The
first 117 patients treated in the study did not receive vitamin
supplementation. The remainder of the patients were treated
with folic acid 350 to 1000 g daily (orally) and vitamin B12
1000 g every 9 weeks (intramuscularly). Patients in the pem-
etrexed-cisplatin arm received a median of six cycles of chemo-
therapy compared with four cycles in the cisplatin arm. Grades
3/4 neutropenia (28%) and leukopenia (18%) were the most
common hematological toxicities. Nonhematological toxicities
(grade 3) included nausea (15%), fatigue (10%), and vomiting
(13%). In general, toxicities were reported more frequently in
the combination arm. Nevertheless, there was a marked reduc-
tion in toxicity for patients who received vitamin supplementa-
tion. All efficacy parameters were superior in the combination
arm (response rate 42% versus 17%, p 0.001; median time to
progression 5.7 versus 3.9 months, p  0.001). The median
survival was 12.1-month with cisplaitn-pemetrexed compared
with 9.3 for cisplatin alone arm (p  0.020). For patients who
received vitamin supplementation, the median survival was 13.3
versus 10 months (p  0.051). Thus, the combination of pem-
etrexed and cisplatin was associated with a tolerable safety
profile and superior efficacy compared with therapy with cispla-
tin alone. This is the first randomized trial to demonstrate a
survival advantage for combination chemotherapy for patients
with MPM. The study also documented improved therapeutic
index with supplementation of vitamin B12, and folic acid for
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patients during therapy with pemetrexed-cisplatin. The provoc-
ative results noted with the cisplatin-pemetrexed combination
has heralded a new era for the treatment of MPM, which until
then was devoid of an approved “standard of care.” The regimen
has been approved for the treatment of patients with advanced
MPM by the Food and Drug Administration.
Pemetrexed can also be safely administered in combi-
nation with carboplatin for the treatment of advanced MPM.
A phase II study evaluated the efficacy of this combination in
patients with previously untreated MPM.59 For the 102 pa-
tients included in the study, the response rate was approxi-
mately 18% and an additional 50% achieved disease stabili-
zation. The median survival and progression-free survival
(PFS) were 12.7 and 6.5 months, respectively. Therapy was
tolerated well and both drugs were administered at nearly
100% of the planned dose intensity. Therefore, the carbopla-
tin and pemetrexed combination can be considered as an
alternative treatment options for patients who are not candi-
dates for cisplatin-based therapy. A phase II study that eval-
uated the nonplatinum combination of pemetrexed and gem-
citabine noted modest survival data that did not compare
favorably with the platinum-pemetrexed regimen.60 An on-
going randomized phase II study by the Eastern Cooperative
Oncology Group compares the carboplatin-pemetrexed regi-
men to gemcitabine-pemetrexed in patients with previously
untreated, advanced stage MPM.
RALTITREXED
Raltitrexed is a folate analog that exerts anticancer
effect by inhibiting thymidilate synthase. A phase II study
demonstrated a response rate of 21% for patients with ad-
vanced MPM with the administration of raltitrexed as mono-
therapy.44 Based on this, a phase III study (Figure 1) was
conducted to evaluate the therapeutic utility of raltitrexed in
MPM (Table 3).47 Advanced stage MPM patients were ran-
domized to therapy with cisplatin alone or in combination
with raltitrexed (3 mg/m2 every 3 weeks). The response rate
was 14% with cisplatin monotherapy compared with 24%
with the combination. Overall survival, the primary end point
of the study, was superior with cisplatin-raltitrexed (11.4
versus 8.8 months). The 1-year survival rate also favored the
combination arm (46% versus 40%). The main adverse
events associated with the combination were neutropenia and
emesis. On the basis of these results, the combination of
cisplatin-raltitrexed is another efficacious alternative for the
treatment of patients with advanced MPM.
CHEMOTHERAPY VERSUS SUPPORTIVE CARE
Recently, the results of a randomized clinical trial that
compared active symptom control (ASC) alone versus ASC
in combination with chemotherapy were reported.61 Either
the combination of mitomycin, vinblastine and cisplatin (four
cycles) or monotherapy with vinorelbine (weekly  12) were
administered. Endpoints included evaluation of survival and
assessment of symptom improvement. The sample size was
reduced during the course of the trial, because of slow
accrual, thus, lowering the statistical power. There was a
nonsignificant trend towards improved median survival with
chemotherapy (8.5 versus 7.6 months). Symptom improve-
ment occurred in all three patient groups, but the differences
were not significant between them. Despite the apparent lack
of benefit with chemotherapy, subset analysis revealed im-
proved outcome for patients treated with vinorelbine in com-
bination with ASC. Only 50 to 60% of the patients received
the planned doses of chemotherapy. Though these results are
disappointing, it should be noted that neither of the chemo-
therapy regimens used in the study were proven to be effi-
cacious for patients with MPM. The low statistical power
could be another contributory factor to the observed lack of
efficacy enhancement with chemotherapy. Because the com-
bination of cisplatin-pemetrexed confers survival advantage,
its use in combination with ASC is the preferred treatment for
patients with MPM.
MOLECULARLY TARGETED AGENTS IN THE
TREATMENT OF MESOTHELIOMA
There are no standard treatment options for patients
who experience disease progression with first-line chemo-
therapy. Currently, these patients are offered the option of
FIGURE 1. Schema of randomized phase III study (Vorinos-
tat versus placebo).
TABLE 3. Phase III Studies in MPM
Author Regimen
Sample
Size
Median
Survival (m)
Response
Rate
Vogelzang et al.45 Cisplatin 222 9.3 17%
Cisplatin-Pemetrexed 226 12.1 41%
Van Meerbeeck et al.47 Cisplatin 124 8.8 14%
Cisplatin-Raltitrexed 126 11.4 24%
Muers et al.61 ASC 136 7.6 Not reported
ASC  MVP 137 7.8
ASC  Vinorelbine 136 9.4
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receiving experimental agents or therapy with a cytotoxic
agents with supporting phase II data. For patients with symp-
tomatic disease and rapidly declining performance status, the
use of supportive care measures alone is appropriate in this
setting. As a result, patients with relatively indolent disease,
who are often treated with second-line therapy and beyond,
tend to have better survival duration, sometimes even better
than that seen with first-line therapy. This underscores the
need for using novel trial designs such as randomized dis-
continuation method or by the use of a control arm with new
agents that are being evaluated in the second-line therapy for
mesothelioma. A number of new agents with unique mecha-
nisms of action are being evaluated for the treatment of
recurrent or refractory MPM.
EPIDERMAL GROWTH FACTOR RECEPTOR
INHIBITORS
Several molecularly targeted therapeutic approached
are currently under evaluation for the treatment of MPM. The
epidermal growth factor receptor (EGFR) is frequently over-
expressed in MPM. On the basis of this observation and
preclinical data that suggested anticancer activity with ge-
fitinib in mesothelioma cell lines, the CALGB group recently
reported the results of a phase II trial that evaluated the role
of gefitinib for the treatment of MPM.62 No objective re-
sponses were noted and regimen was not deemed suitable for
further evaluation. Erlotinib, another EGFR inhibitor, was
also evaluated in a phase II study for patients with MPM.63
No objective responses were seen despite a high rate of
patients with EGFR expressing tumors (75%) in the study.
Disease stabilization was noted in 15 of 33 patients with
measurable disease.
ANTIANGIOGENIC AGENTS
Agents that inhibit the angiogenesis pathways are cur-
rently under investigation for the treatment of MPM. This is
based on the observation of high levels of circulating vascular
endothelial growth factor (VEGF) in patients with MPM.
Furthermore, MPM tumors often tend to have high microves-
sel density, which has been linked with a poor outcome.64
Bevacizumab, a monoclonal antibody against the VEGF, is
approved for the treatment of colon and nonsquamous non-
small cell lung cancer, in combination with chemotherapy. A
randomized phase II study was conducted for patients with
advanced MPM to evaluate whether the addition of bevaci-
zumab results in enhancement of the efficacy of chemother-
apy.65 Patients were treated with the regimen of cisplatin and
gemcitabine with or without bevacizumab. The treatment was
tolerated well without any major toxicity. Nevertheless, there
was no suggestion of improved outcome with the addition of
bevacizumab. The median PFS, the primary end point was
6.9 and 6.0 months, respectively, with and without the addi-
tion of bevacizumab. Though the overall median survival was
numerically superior for bevacizumab  chemotherapy (15.6
versus 14. 7 months), the difference was not statistically
significant (p  0.91). An exploratory subset analysis noted
improved survival with bevacizumab-chemotherapy regimen
in patients with low circulating levels of VEGF.
Phase II studies are also underway to evaluate small
molecule inhibitors of the VEGF receptor tyrosine kinase.
Sorafenib was evaluated as monotherapy for recurrent MPM
in a phase II study by the CALGB.66 Though treatment was
tolerated well, the response rate of 4% did not meet the
criteria for further evaluation of this agent as monotherapy in
MPM. The study allowed patients with no prior therapy in
addition to those who had progressed after one prior regimen.
The median survival duration was 4.9 months in chemother-
apy-naive patients and 14.9 months in those who had re-
ceived prior therapy. This difference is probably a function of
patient selection, as mentioned earlier. Vatalanib, another
VEGF tyrosine kinase inhibitor has also been studied in this
setting.67 In a study of 47 patients, this agent was associated
with an objective response in five patients and a median
survival of 10 months. However, the study did not meet the
prespecified end point of 3-month PFS rate to warrant further
investigation. Other VEGF tyrosine kinase inhibitors that are
currently under evaluation for the treatment of MPM include
sunitinib, cediranib, vatalanib, and pazopanib. Because these
agents have varying kinase inhibition profiles, it is hoped that
they would be active agents for the treatment of MPM.
HISTONE DEACETYLASE INHIBITORS
Histone deacetylase (HDAC) inhibitors are novel anti-
cancer agents that act by a variety of mechanisms. Histones
are the core-proteins in the center of the DNA double helix.
The histone proteins exist in either a nonacetylated transcrip-
tionally inactive configuration or an acetylated state that is
open to gene transcription. The dynamic equilibrium between
the acetylated and nonaceylated forms is mediated by histone
acetyltransferase and HDAC.68 Agents that inhibit HDAC
have recently demonstrated promising anticancer activity in
early phase clinical trials. Vorinostat (Zolinza) is a small
molecule inhibitor of HDAC that is approved by the FDA for
the treatment of advanced, relapsed, or refractory cutaneous T
cell lymphoma.52,53 In addition to its inhibitory effect on
HDAC, vorinostat also acetylates several key cell signaling
proteins that play a role in regulating normal cell differenti-
ation, apoptosis, and proliferation. Therefore, both histone
and nonhistone protein-mediated effects of HDAC inhibitors
are thought to be responsible for their anticancer effects.54
Initial studies of vorinostat have demonstrated objec-
tive responses in patients with MPM. In the initial phase I
studies with the oral formulation of vorinostat, 13 patients
with advanced MPM were included.69 Twelve out of these
patients had received prior systemic chemotherapy for MPM.
Two objective partial responses were noted and four patients
received six cycles of therapy. The treatment regimen was
tolerated well. Given the lack of proven options for salvage
therapy for MPM, these promising results have prompted the
initiation of a large randomized clinical trial to compare
vorinostat to placebo. In this ongoing study, patients who
received one or two prior regimens for advanced MPM are
eligible. The primary end point is the determination of overall
survival.
The mechanistic aspects of the efficacy noted with
vorinostat in MPM are unclear. Because inhibitors of TS have
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demonstrated activity in MPM, it is conceivable that repres-
sion of TS and cytidine triphosphate synthetase by HDAC
inhibitors could play a role. Another mechanism may be the
induction of apoptosis, which has been demonstrated with
preclinical studies of sodium butyrate, a HDAC inhibitor, in
mesothelioma cell lines.56,57 HDAC inhibitors have also been
shown to block angiogenic signaling by inhibiting VEGF-
induced expression of VEGF receptors.70 Furthermore, hy-
poxia-inducible factor-1 alpha, a key molecule that stimulates
VEGF secretion, is regulated by acetylation mechanism.59 It
is hoped that ongoing studies with correlative science end-
points will shed more light in this front.
OTHER NOVEL AGENTS
A novel agent that has entered phase III evaluation in
mesothelioma is ranpirnase, a cytotoxic amphibian ribonu-
clease. It induces apoptosis independently of p53 protein. The
efficacy of ranpirnase was evaluated in a phase II study for
patients with advanced MPM.71 The study reported promising
survival duration of 8.3 months. Importantly, objective re-
sponses were noted in 4 out of 81 patients with measurable
disease. A large ongoing study (N  428 patients) random-
izes patients with MPM to therapy with doxorubicin in
combination with or without ranpirnase. The study has com-
pleted accrual and the results are eagerly awaited. Other
novel agents that have been evaluated in this setting include
imatinib, an inhibitor of c-kit and bcr-abl tyrosine kinases. No
objective responses were noted in a cohort of 25 patients with
advanced MPM.72
Recent studies have documented that Src kinase, a
nonreceptor tyrosine kinase is activated in tumors of patients
with MPM.73 Activation of this pathway has been linked with
advanced stage and poor outcome in patients with MPM.
Therefore, an ongoing phase II study is evaluating the role of
dasatinib, an inhibitor of the Src kinase, for the treatment of
patients with relapsed or refractory MPM.
Mesothelin is a glycosyl-phosphatidyl inositol-linked
membrane protein of overexpressed in mesothelioma.74 It
seems to play an important role in cell adhesion by its interaction
with MUC-1 (epithelial membrane antigen) 16. Morphotek an-
tibody-009 is a mouse-human chimeric IgG1kappa monoclonal
antibody with high affinity for human mesothelin. It has been
shown to elicit cell-mediated immunity against cells bearing
the mesothelin antigen. Based on this, clinical trials have been
initiated to evaluate the utility of this agent in the treatment of
malignancies that express mesothelin.
Vaccine approaches are also under investigation for the
treatment of MPM. Wilm’s tumor associated gene (WT)-1 is
a transcription factor expressed in tissues of mesodermal
origin during embryogenesis. Up-regulation of WT-1 has
been linked with tumorigenesis of various malignancies in-
cluding mesothelioma and is an attractive target for immu-
notherapy.75 Therefore, WT-1 peptide epitopes that stimulate
T-cell immunity are currently under evaluation for the treat-
ment of mesothelioma. Preliminary results from ongoing
studies have documented the safety of this vaccine.
CONCLUSIONS
MPM remains a difficult and growing problem. Surgi-
cal resection for patients with early stage MPM is considered
standard therapy. Radiation has palliative benefit. For patients
with advanced disease, combination chemotherapy with cis-
platin and pemetrexed results in improvement in survival and
quality of life, thus constituting the “standard of care.”
Molecularly targeted approaches are currently being studied
for the treatment of MPM. Though the initial experience with
inhibitors of the EGFR pathway and VEGF-pathway have
been disappointing, the promising data noted with HDAC
inhibitors have generated a renewed enthusiasm for evalua-
tion of novel agents in this setting.
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